TYTakahisa Yamashita

Takahisa Yamashita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takahisa Yamashita has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Morihiro Higashi

    Department of pathology Saitama Medical Center, Saitama Medical University kawagoe, Saitama Japan

    3 shared publications
  • Shuji Momose

    Department of pathology Saitama Medical Center, Saitama Medical University kawagoe, Saitama Japan

    3 shared publications
  • Akihiro Yano

    Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan

    2 shared publications
  • Kazuki Yokota

    Department of Urology Saitama Medical Center, Saitama Medical University Kawagoe Japan

    2 shared publications
  • Kenta Fujii

    Department of Urology Saitama Medical Center, Saitama Medical University Kawagoe Japan

    2 shared publications
  • Morihiro Higashi

    Department of Pathology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan

    2 shared publications

Latest Publications

  • Open Access

    Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin‐4 Expression: A Case Report

    by Sonin Chon, Shoichi Nagamoto, Takahisa Yamashita, Kenta Fujii, Kazuki Yokota, Kojiro Tachibana, Sachi Kitayama, Yohei Okada, Satoru Kawakami, Akihiro Yano

    Introduction: Sarcomatoid urothelial carcinoma (UC) is an extremely rare and aggressive subtype with a poor prognosis. Reports on the efficacy of enfortumab vedotin (EV) in this subtype remain limited. Case Presentation: A 74‐year‐old man presented with gross hematuria and was diagnosed with metastatic sarcomatoid UC of the urinary bladder with Nectin‐4 expression. First‐line chemotherapy with gemcitabine plus carboplatin therapy was initiated; however, lymph node metastases progressed. After second‐line pembrolizumab therapy, new pulmonary and para‐aortic lymph node metastases developed. Third‐line EV therapy achieved a partial response in the bladder cancer and complete response in metastatic lesions. The patient subsequently underwent robot‐assisted radical cystectomy with ileal conduit diversion, and pathological examination revealed no residual carcinoma (ypT0N0). He has remained disease‐free for 30 months without additional therapy. Conclusion: EV may induce substantial and clinically meaningful responses in selected patients with metastatic sarcomatoid UC expressing Nectin‐4, even after failure of platinum‐based chemotherapy and immune checkpoint inhibition.

  • Open Access

    Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma

    by Takahisa Yamashita, Shoichi Nagamoto, Masahiro Arai, Sachi Kitayama, Akihiro Yano, Morihiro Higashi

    Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.


  • Open Access

    Immunoglobulin G4‐Related Inflammatory Pseudotumor With Cystic Features Mimicking Renal Cancer

    by Yuki Tanaka, Takahisa Yamashita, Kazuki Yokota, Kenta Fujii, Sachi Kitayama, Shoichi Nagamoto, Hideki Takeshita, Yohei Okada, Satoru Kawakami, Akihiro Yano

    Introduction: Immunoglobulin G4‐related disease is a systemic fibroinflammatory disorder that affects the kidney, presenting as an immunoglobulin G4‐related inflammatory pseudotumor. These renal inflammatory pseudotumors are usually solid, and cystic presentations have not been previously described.Case Presentation: We report a 77‐year‐old man who presented with a Bosniak category III renal cystic mass and periaortic fibrous thickening. Increased serum immunoglobulin G4 levels indicated immunoglobulin G4‐related disease; however, a malignant process could not be definitively ruled out. The patient underwent robot‐assisted radical nephrectomy, and histopathologic assessment confirmed a cystic immunoglobulin G4‐related inflammatory pseudotumor.Conclusion: This is the first report of a renal immunoglobulin G4‐related inflammatory pseudotumor with cystic features. Increased knowledge of immunoglobulin G4‐related disease as a potential cause of cystic renal lesions, particularly in patients with systemic findings, may improve preoperative diagnosis.

  • Evaluation of NANOG/HDAC1 Expression in Predicting Outcomes of BCG Therapy in Non‐Muscle Invasive Bladder Cancer

    by Takahisa Yamashita, Morihiro Higashi, Mami Yamazaki, Hiroki Imada, Natsuko Takayanagi, Tomomi Shimizu, Keisuke Sawada, Wataru Yamamoto, Chiaki Murakami, Marino Nagata, et al.

    Urinary bladder cancer includes non‐muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). While patients with NMIBC have a better prognosis, NMIBC often recurs, requiring long‐term surveillance and repeated treatments. Intravesical Bacillus Calmette‐Guérin (BCG) therapy is standard for high‐grade or recurrent NMIBC; however, 30%–50% of patients failed to respond, and the mechanisms of resistance remain unclear. To identify predictive biomarkers for response to intravesical BCG therapy, we analyzed NANOG and Histone deacetylase 1 (HDAC1) expression in 90 bladder cancer specimens from NMIBC patients treated with BCG therapy using immunohistochemistry. The correlation between NANOG and HDAC1 expression and clinical outcomes, including response to BCG therapy, was assessed. High‐grade NMIBC cases showed significantly higher expression of NANOG and HDAC1 compared to low‐grade cases (p < 0.05). Additionally, elevated NANOG expression in combination with HDAC1, was associated with poor response to BCG therapy and decreased lymphocyte infiltration in the tumor‐microenvironment. NANOG is suggested to directly increases HDAC1 expression, which could suppress lymphocyte infiltration in the tumor microenvironment by altering immune‐related gene expression. These findings suggest that the NANOG/HDAC1 axis plays a key role in predicting resistance to intravesical BCG therapy in NMIBC.


  • Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer

    by Takahisa Yamashita, Morihiro Higashi, Hironori Sugiyama, Makoto Morozumi, Shuji Momose, Jun-Ichi Tamaru


  • Open Access

    Small bowel intussusception secondary to intestinal submucosal cyst in an infant

    by Seiichiro Inoue, Akio Odaka, Yuki Muta, Shohei Maruta, Yuta Takeuchi, Yoshifumi Beck, Takahisa Yamashita


  • Fluorescent nanoparticle‐mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B‐cell lymphoma

    by Natsuko Takayanagi, Shuji Momose, Jun Kikuchi, Yuka Tanaka, Tomoe Anan, Takahisa Yamashita, Morihiro Higashi, Michihide Tokuhira, Masahiro Kizaki, Jun‐Ichi Tamaru

    The current World Health Organization (WHO) classification defines a new disease entity of high‐grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, making fluorescence in situ hybridization (FISH) screening for these genes mandatory. In addition, the prognostic significance of MYC expression was reported, with a cut‐off value of 40%. However, interobserver discrepancies arise due to the heterogeneous intensity of MYC expression by immunohistochemistry. Moreover, a cut‐off value of positivity for MYC protein in diffuse large B‐cell lymphoma (DLBCL) varies among studies at present. Here, we applied a high‐sensitivity semiquantitative immunohistochemical technique using fluorescent nanoparticles called phosphor‐integrated dots (PID) to evaluate the MYC expression in 50 de novo DLBCL cases, and compared it with the conventional diaminobenzidine (DAB)‐developing system. The high MYC expression detected by the PID‐mediated system predicted poor overall survival in DLBCL patients. However, we found no prognostic value of MYC protein expression for any cut‐off value by the DAB‐developing system, even if the intensity was considered. These results indicate that the precise evaluation of MYC protein expression can clarify the prognostic values in DLBCL, irrespective of MYC rearrangement.


  • Open Access

    Retroperitoneal Cystic Nodal Metastasis of Renal Cell Carcinoma

    by Takahisa Yamashita, Makoto Morozumi, Morihiro Higashi, Shuji Momose, Jun-Ichi Tamaru

    Cystic nodal metastasis of renal cell carcinoma is very rare. The pathogenesis of cystic nodal metastasis is thought to involve obstruction of a lymphoid vessel draining the kidney by tumor cells and retrograde metastasis from the primary site to the lymph node along the lymphatic vessels. In this study, a surgical case of small renal cell carcinoma with retroperitoneal cystic nodal metastasis is reported.